Supplementary Appendix
|
|
- Jeffery Walsh
- 5 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: White DB, Angus DC, Shields A-M, et al. A randomized trial of a family-support intervention in intensive care units. N Engl J Med 2018;378: DOI: /NEJMoa
2 SUPPLEMENTARY MATERIALS FOR: A Randomized Trial of a Family Support Intervention Delivered by the Interprofessional Clinical Team in Intensive Care Units Table of Contents: Pages List of Investigators 1 Table S1. Costs to Deploy the Intervention 2 Figure S1. Stepped Wedge Allocation of Trial Patients and Surrogates 3 Table S2: Characteristics of enrolled patients and surrogates 4 Table S3. Comparison of characteristics of patients whose surrogate completed versus did not consent to 6-month interview Figure S2a-j. Sensitivity analyses: intervention effects across time and within individual centers Exploratory analysis of survival time through 6-month follow-up 17 Table S4a-c. Effect of the PARTNER intervention on HADS subscale scores 18 Table S5. Main Study Outcome Measures Treated as Categorical Variables 19 Table S6. Effect of PARTNER Intervention on surrogates psychological distress stratified by whether the patient survived the index hospitalization 20 Trial Registration and Designation as Quality Improvement Project 21 Schedule of PARTNER Program 12-Hour Communication Skills Training PARTNER Question Prompt List 24 Comparison of PARTNER intervention and SUPPORT intervention 25 0
3 List of Investigators Douglas B. White, MD, MAS 1 Derek C. Angus, MD, MPH, FRCP 2 Anne-Marie Shields, MSN, RN 1 Praewpannarai Buddadhumaruk, MS, RN 1 Caroline Pidro, BS 2 Cindy Paner, RN, MSN 3 Elizabeth Chaitin, MSW, MA, DHCE 9 Chung-Chou H. Chang, PhD 2,4 Francis Pike, PhD 5 Lisa Weissfeld, PhD 6 Jeremy M. Kahn, MD, MS 2 Joseph M. Darby, MD 7 Amy Kowinsky, RD, LDN 3 Susan Martin RN, MSN 3 Robert M. Arnold, MD 8,9 On behalf of the Pairing Re-engineered Intensive Care Teams with Nurse-driven Emotional Support and Relationship building (PARTNER) Investigators 1 Program on Ethics and Decision Making, The Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 2 The CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 3 The Wolff Center at UPMC, UPMC Health System, Pittsburgh, PA, USA 4 Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 5 Eli Lilly and Company, Indianapolis, IN, USA 6 Statistics Collaborative; 1625 Massachusetts Ave. NW; Suite 600; Washington DC Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 8 Department of General Internal Medicine, Section of Palliative Care and Medical Ethics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 9 Palliative and Supportive Institute, UPMC Health System, Pittsburgh, PA, USA Funding Source: UPMC Innovation Award; The Greenwall Foundation Trial Registration Number: NCT Address for correspondence: Douglas B. White, MD, MAS Program on Ethics and Decision Making in Critical Illness Department of Critical Care Medicine University of Pittsburgh School of Medicine 3550 Terrace St, Scaife Hall, Room 608 Pittsburgh, PA whitedb@upmc.edu 1
4 TABLE S1. Costs to Deploy the Intervention 12-hour communication skills training course for staff nurses at each site. Ten daily site visits by QI specialist at beginning of intervention phase at each site (4 hours each). Description of Expenses Hourly wages for nurses being trained, time of 2 medical actors, 1 instructor, and QI implementation specialist; printed training materials, facility rental, and meals for all attendees. Hourly wage of QI implementation specialist; parking and travel expenses. Cost (in U.S.D) $23, $11, Weekly site visits by QI implementation specialist throughout intervention phase at each site (4 hours each). Hourly wage of QI implementation specialist; parking and travel expenses. $58, TOTAL COST $92, Costs per patient who received the $ intervention (N=547) 2
5 Figure S1. Stepped Wedge Allocation of Trial Patients and Surrogates Study ICU Step 0 Step 1 Step 2 Step 3 Step 4 Step 5 Total 1 65 Patients enrolled 52 Surrogates agreed to follow-up 36 Completed follow up Patients enrolled 103 Surrogates agreed to follow-up 65 Completed follow up Patients enrolled 168 Surrogates agreed to follow-up 127 Completed follow up Patients enrolled 197 Surrogates agreed to follow-up 158 Completed follow up 208 Patients enrolled 159 Surrogates agreed to follow-up 119 Completed follow up 106 Patients enrolled a 75 Surrogates agreed to follow-up 53 Completed follow up 114 Patients enrolled 108 Surrogates agreed to follow-up 72 Completed follow up 67 Patients enrolled b 41 Surrogates agreed to follow-up 28 Completed follow up 273 Patients enrolled 211 Surrogates agreed to follow-up 155 Completed follow up 242 Patients enrolled 178 Surrogates agreed to follow-up 118 Completed follow up 337 Patients enrolled 276 Surrogates agreed to follow-up 199 Completed follow up 322 Patients enrolled 238 Surrogates agreed to follow-up 186 Completed follow up Patients enrolled 157 Surrogates agreed to follow-up 115 Completed follow up White shading= usual care; Blue shading = intervention a Last patient enrolled on 7/1/2014 because this ICU was closed by the hospital administration. b ICU decreased in size from 28 beds to 20 beds on 7/1/ Patients enrolled 46 Surrogates agreed to follow-up 36 Completed follow up 246 Patients enrolled 203 Surrogates agreed to follow-up 151 Completed follow up TOTAL 1420 Patients enrolled 1106 Surrogates agreed to follow-up 809 Completed follow up 3
6 Table S2: Characteristics of enrolled patients and surrogates Patient Characteristic Control (n=873) Intervention (n=547) p-value a Age, mean (SD) 63.3 (15.5) 67.5 (14.9) <0.001 Female, count (%) 405 (46.4) 290 (53.0) 0.02 Race, count (%) White Black Hispanic Other Not documented Primary Diagnosis, count (%) Cardiovascular Pulmonary GI Toxicology Infection/Sepsis Neurological Oncological Other Admission source, count (%) Direct Emergency Other hospital Skilled nursing facility 708 (81.1) 64 (7.3) 2 (0.2) 9 (1.0) 90 (10.3) 36 (4.1) 138 (15.9) 94 (10.8) 38 (4.4) 212 (24.4) 173 (19.9) 59 (6.8) 118 (13.6) 224 (25.7) 549 (62.9) 100 (11.5) (83.9) 43 (7.9) 0 4 (0.7) 41 (7.5) 33 (6.0) 107 (19.6) 49 (9.0) 18 (3.3) 159 (29.1) 106 (19.4) 18 (3.3) 56 (10.3) 50 (9.1) 422 (77.2) 73 (13.4) 2 (0.4) 0.30 <0.01 <0.001 Modified SAP II score, mean (SD) 49.4 (12.0) 51.0 (11.8) 0.02 Elixhauser comorbidity index (count; range 0-29), mean (SD) 5.1 (2.5) 5.8 (2.4) <0.001 On mechanical ventilation during hospitalization, count (%) 759 (86.9) 479 (87.6) 0.73 Surrogate Characteristic Control (n=677) Intervention (n=429) p-value Age, mean (SD) 56.4 (13.6) 57.1 (13.7) 0.46 Female, count (%) 480 (70.9) 284 (66.2) 0.06 Race, count (%) White Black Hispanic Asian Multiethnic Not documented Relationship to Patient Spouse/partner Parent Child Sibling Other relative Other relationship Not documented a From Student s t-test or Pearson's chi-squared test 559 (82.6) 37 (5.5) 5 (0.7) 6 (0.9) 3 (0.4) 67 (9.9) 295 (43.6) 63 (9.3) 197 (29.1) 81 (12.0) 18 (2.7) 20 (3.0) 3 (0.4) 383 (89.3) 36 (8.4) 0 (0) 2 (0.5) 2 (0.5) 6 (1.4) 161 (37.5) 28 (6.5) 163 (38.0) 53 (12.4) 12 (2.8) 9 (2.1) 3 (0.7)
7 Table S3. Comparison of characteristics of patients whose surrogate completed versus did not consent to 6-month interview Patient characteristics Did not complete 6 month followup (n=611) Completed 6 month follow up (n=809) p-value a Total Age, mean (SD) 64.9 (15.2) 64.9 (15.6) (15.4) Female, No. (%) 309 (50.6) 386 (47.7) (48.9) Race, No. (%) White Black Hispanic Other Not documented Primary Diagnosis, count (%) Cardiovascular Pulmonary GI Toxicology Infection/Sepsis Neurological Oncological Other Not documented Admission source, No. (%) Direct Emergency Other hospital SNF 538 (81.0) 66 (9.9) 1 (0.2) 8 (1.2) 51 (7.7) 28 (4.6) 102 (16.7) 61 (10.0) 27 (4.4) 174 (28.5) 115 (18.8) 35 (5.7) 66 (10.8) 3 (0.5) 674 (83.3) 48 (5.9) 1 (0.1) 5 (0.6) 81 (10.0) 41 (5.1) 143 (17.7) 82 (10.1) 29 (3.6) 197 (24.4) 164 (20.3) 42 (5.2) 108 (13.4) 3 (0.4) (82.3) 114 (7.7) 2 (0.1) 13 (0.9) 132 (9.0) 69 (4.9) 245 (17.3) 143 (10.1) 56 (3.9) 371 (26.1) 279 (19.7) 77 (5.4) 174 (12.3) 6 (0.4) 109 (17.8) 422 (69.1) 80 (13.1) (20.4) 549 (67.9) 93 (11.5) 2 (0.3) (19.3) 971 (68.4) 173 (12.2) 2 (0.1) Modified SAP II score, mean (SD) 50.2 (12.1) 49.8 (11.8) (11.9) Elixhauser comorbidity index score (0-29), mean (SD) 5.5 (2.6) 5.3 (2.5) (2.5) Received mechanical ventilation during the hospitalization, No. (%) 526 (86.1) 712 (88.0) (87.1) a From Student s t-test or Pearson's chi-squared test 5
8 Figure S2a-h. Sensitivity analyses: intervention effects across time and within individual centers We conducted post-hoc sensitivity analyses to assess the robustness of the main findings, following recommendations for such analyses in stepped wedge randomized controlled trials (Davey C, et al. Analysis and reporting of stepped wedge randomized controlled trials: synthesis and critical appraisal of published studies, 2010 to Trials 2015; 16:358). First, we assessed whether the effects of the intervention were consistent over time during the study period. Second, we assessed whether the effects of the intervention were consistent across sites. Overall, these exploratory analyses support the robustness of the findings across individual sites and individual time steps. We used two approaches to assess for heterogeneity of treatment effect over time. First, we assessed for interactions between treatment and the fixed effect for time. To check for interactions between treatment and time, we included a variable for time step (time step=0 to time step=5) and an interaction variable between this time step and PARTNER intervention in the multivariable linear regression models, adjusted for the same variable listed in Table 2. Second, we reran the multivariable regression models stratified by time, then plotted the treatment effect across time to allow for visual comparison. For this analysis, we used the same multivariable linear regression models in Table 2 but restricted the analyzing cohort to those enrolled between time 0 to the end of time step t (where t=1, 2, 3, or 4). Therefore, we obtained a total of 4 stratified models for each outcome. We used two approaches to assess for heterogeneity of treatment effect across individual ICUs. First, we assessed for interactions between treatment and the ICU fixed effect. To check for interactions between treatment and ICU fixed effect we included a variable for site and interaction variable between PARTNER intervention and site into the multivariable linear regression models, adjusted for the same variable listed in Table 2. Second, we refit the multivariable regression models stratified by ICUs, then plotted the treatment effect in individual ICUs to allow for visual comparison. To refit the models stratified by ICU, we used the same multivariable linear regression models in Table 2 but restricted the analyzing cohort to each site. Therefore, we obtained a total of 5 stratified models for each outcome. 6
9 Magnitude of effect size on QOC Figure S2a. Effect of PARTNER intervention across time on Quality of Communication (QOC) score with 95% CI Overall effect End of time step t size Summary of findings in S2a. After adjusting for patient s age, race, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, and admission source, the intervention significantly improved surrogates perceptions of the quality of communication (QOC scale; β=6.39 (95% CI 2.57 to 10.20; p=0.001). Overall, there was no difference across time in the QOC score; the interaction between treatment and time fixed effect was not statistically significant (p=0.08). Visual inspection of the effect over time revealed that there was a positive effect in all time steps. 7
10 Magnitude of effect size on PPPC Figure S2b. Effect of PARTNER intervention across time on the patient- and familycenteredness of care score (with 95% CI) Overall effect size End of time step t Summary of findings in S2b. After adjusting for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, admission source, surrogate s age and gender, the PARTNER intervention improved surrogates perceptions of the patient- and familycenteredness of care (β (95% CI to -0.04; p=0.006). Overall, there was no difference across time in the PPPC score; the interaction between treatment and time fixed effect was not statistically significant (p= 0.77). Visual inspection of the figure displaying stratification by time revealed that there was a similar effect of the PARTNER intervention on surrogates perceptions of the patient- and family-centeredness of care in all time steps. 8
11 Magnitude of effect size on HADS Figure S2c. Adjusted estimated effect of PARTNER intervention across time on total HADS score with 95% CI Overall effect size End of time step t Summary of findings in Figure S2c: Overall, there was no significant difference between groups in the HADS score (β (95% CI to 0.99; p=0.62) after adjusting for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient. There was no difference across time in the HADS score; the interaction between treatment and time fixed effect was not statistically significant (p=0.10). Visual inspection of the figure displaying stratification by time revealed that there was a similar effect of the PARTNER intervention on surrogates HADS scores in all time steps. 9
12 Magnitude of effect size on IES Figure S2d. Adjusted estimated effect of PARTNER intervention across time on IES score with 95% CI Overall effect size End of time step t Summary of findings in S2d. Overall there was no significant effect of the intervention on surrogates post-traumatic stress symptoms, measured with the IES, after adjusting for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient (β: 0.90 (95% CI to 3.47; p=0.49). There was no difference across time in the IES score; the interaction between treatment and time fixed effect was not statistically significant (p= 0.97). Visual inspection of the figure displaying stratification by time revealed that there was a similar effect of the PARTNER intervention on surrogates IES score in all time steps. 10
13 Magnitude of effect size on ICU LOS among decedents Figure S2e. Adjusted estimated effect of PARTNER intervention across time on ICU length of stay (LOS) among in-hospital decedents (IRR with 95% CI) Overall effect size End of time step t Summary of findings in S2e. Overall there was no difference across time in ICU LOS among decedents (IRR 0.64; 95% CI 0.52 to 0.78; p<0.001). The interaction between treatment and time fixed effect was not statistically significant (p=0.516). Stratification by time step showed no significant change in the intervention s effect on ICU LOS across time. 11
14 Magnitude of effect size on QOC Figure S2f. Adjusted estimated effect of PARTNER intervention by site on QOC score (with 95% CI) ICU1 ICU2 ICU3 ICU4 ICU5 Overall effect size Site Summary of findings in S2f. After adjusting for patient s age, race, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, and admission source, the intervention significantly improved surrogates perceptions of the quality of communication (QOC scale), β 6.39 (95% CI 2.57 to 10.20; p=0.001). There was no significant heterogeneity of treatment effect across sites as evidenced by the non-significance of the interactions between treatment and ICU fixed effect (p= Visual inspection of the figure displaying site-specific estimates of effect size reveals all ICUs with similar effects. 12
15 Magnitude of effect size on PPPC Figure S2g. Adjusted estimated effect of PARTNER intervention on PPPC score with 95% CI by site ICU1 ICU2 ICU3 ICU4 ICU5 Overall effect size Site Summary of findings in S2g. After adjusting for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, admission source, surrogate s age and gender, the PARTNER intervention improved surrogates perceptions of the patient- and familycenteredness of care (β (95% CI to -0.04; p=0.006). The treatment effect was consistent across sites as evidenced by the non-significance of the interactions between treatment and ICU fixed effect (p=0.14). Visual inspection of the figure displaying site-specific estimates of effect size reveals all ICUs showed improvements in the patient- and familycenteredness of care in the ICU (i.e., reduced scores on the scale). 13
16 Magnitude of effect size on HADS Figure S2h. Adjusted estimated effect of PARTNER intervention by site on total HADS score with 95% CI ICU1 ICU2 ICU3 ICU4 ICU5 Overall effect size Site Summary of findings in Figure S2h: Overall, there was no significant difference between groups in the HADS score (β (95% CI to 0.99; p=0.62). While site effect was not statistically significant (p=0.62), the interaction between treatment and ICU fixed effect was statistically significant (p=0.04). Running an analysis stratified by ICU revealed that one ICU differed from the other 4 ICUs in terms of detecting a significant improvement in HADS scores (β -3.91; 95% CI to -0.20; p=0.04), whereas the was no significant heterogeneity across the other ICUs. Of note, the one ICU that drove the positive heterogeneity test had the fewest patients in the control arm (n=34) raising questions about the stability of the estimate of the treatment effect in the control arm. 14
17 Magnitude of effect size on IES Figure S2i. Adjusted estimated effect of PARTNER intervention on IES score with 95% CI by site ICU1 ICU2 ICU3 ICU4 ICU5 Overall effect size Site Summary of findings in S2i. Overall there was no significant effect of the intervention on surrogates post-traumatic stress symptoms, measured with the IES, after adjusting for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, primary diagnosis, admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient (β: 0.90 (95% CI to 3.47; p=0.49). There was not a significant interaction between treatment and ICU fixed effect (p= 0.077). On visual inspection of the sitespecific effects in Figure S8d, the 95% CI of the effect size overlapped across all 6 ICUs. 15
18 Effect size on ICU LOS among decedents (IRR) Figure S2j. Adjusted effect of PARTNER intervention by site on ICU length of stay (LOS) among in-hospital decedents (IRR with 95% CI) ICU1 ICU2 ICU3 ICU4 ICU5 Overall effect size Site Summary of findings in S2j: The overall effect of PARTNER intervention on ICU LOS among decedents adjusted for site is IRR 0.64 (95% CI 0.52 to 0.78; p<0.001). The interaction between treatment and ICU fixed effect was not statistically significant (p=0.238). Running an analysis stratified by ICU revealed that the intervention decreased ICU LOS across all sites. 16
19 Exploratory analysis of survival time through 6-month follow-up Approach and findings: To assess whether the intervention affected survival time over 6-month follow-up, we conducted an exploratory analysis using Gray s semiparametric survival regression model, adjusting for time, ICU site, age, having mechanical ventilation, modified SAPS III score, and primary diagnosis. We assessed the proportional hazards (PH) assumption for each covariate using Gray s test (1992). We treated covariates that violated the PH assumption as time-varying. We treated all other covariates as constant in the model. ICU was treated as a fixed effect. The covariates that significantly violated the PH assumption were treatment, time, ICU, age, and primary diagnosis. In the final adjusted model, there was no statistically significant effect on duration of survival within the 6-months of combined inpatient and outpatient follow up (HR=1.25, 95% CI: ; p-value=0.09). These findings are consistent with the main outcome analysis of 6-month survival, which found no statistically significant difference in the proportion of patients alive at 6 months. Reference Gray, RJ (1992). Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. Journal of the American Statistical Association, 87,
20 Table S4a. Effect of the PARTNER intervention on HADS subscale scores Control (n=501) Intervention (n=308) Unadjusted p-value a Intervention effect (95% CI) 7.1 (4.7) 6.7 (4.3) 0.21 β c (-0.99 to 0.50) 4.9 (4.4) 5.0 (4.3) 0.91 β c HADS anxiety subscale (range 0-21), mean (SD) HADS depression subscale (range 0-21), mean (SD) (-0.80 to 0.60) a From Student s t-test b Adjusted for site, patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, and admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient. c β=linear regression coefficient. Results from adjusted linear regression model. Adjusted p-value b Table S4b. Effect of the PARTNER intervention on HADS subscale categories: normal, borderline abnormal, and abnormal. HADS anxiety subscale category 0-7 Normal 8-10 Borderline abnormal Abnormal HADS depression subscale category 0-7 Normal 8-10 Borderline abnormal Abnormal Control (n=501) 285 (58.2) 91 (18.6) 114 (23.3) 373 (76.1) 53 (10.8) 64 (13.1) Intervention (n=308) 182 (59.3) 70 (22.8) 55 (17.9) 233 (75.9) 37 (12.1) 37 (12.1) Unadjusted p-value a Intervention effect (95% CI) 0.12 OR 0.93 c (0.67 to 1.30) 0.82 OR 0.89 c (0.59 to 1.33) a From Student s t-test b Adjusted for site, patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, and admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient. c OR=odds ratio. Results from adjusted ordinal logistic regression model. Adjusted p-value b Table S4c. Effect of the PARTNER intervention on HADS subscale binary categories: normal vs abnormal HADS anxiety subscale, count, (%) 0-10 Normal Abnormal HADS depression subscale, count, (%) 0-10 Normal Abnormal Control (n=501) 376 (76.7) 114 (23.3) 426 (86.9) 64 (13.1) Intervention (n=308) 252 (82.1) 55 (17.9) 270 (88.0) 37 (12.1) Unadjusted p-value a Intervention effect (95% CI) 0.07 OR 0.73 c (0.48 to 1.13) 0.68 OR 0.73 c (0.43 to 1.25) a From Student s t-test b Adjusted for site, patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, and admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient. c OR= odds ratio. Results from adjusted logistic regression model. Adjusted p-value b
21 Table S5. Main Study Outcome Measures Treated as Categorical Variables Control (n=501) Intervention (n=308) a Unadjusted p-value Intervention effect (95% CI) Adjusted p-value b Surrogates Psychological Symptom Burden c Hospital Anxiety and Depression Scale category; No. (%) Normal (0-14) Borderline abnormal (15-21) Abnormal (22-42) Refused HADS assessment Impact of Events Scale category, No. (%) No concern (0 score<24) Partial PTSD (24 score<33) Probable PTSD (33 score<37) PTSD (37 score 88) Refuse IES assessment 333 (66.5) 80 (16.0) 77 (15.4) 11 (2.2) 316 (63.1) 73 (14.6) 17 (3.4) 79 (15.8) 16 (3.2) 206 (66.9) 62 (20.1) 39 (12.7) 1 (0.3) 190 (61.7) 40 (13.0) 22 (7.1) 53 (17.2) 3 (1.0) 0.06 OR 0.96 d,e (0.67 to 1.37) 0.04 OR 1.29 e ( ) Communication and Decision Making Outcomes Quality of Communication Scale OR (30.5) 126 (41.0) f,g score 80, No. (%) (1.17 to 2.30) Patient- and family-centeredness, No. (%) 3<score 4 38 (7.6) 14 (4.6) OR 2.03 <0.001 e,h 2<score (27.9) 50 (16.2) (1.41 to 2.93) 1 score (62.7) 244 (79.2) Refused assessment 9 (1.8) 0 (0) a From Pearson's chi-squared test b All models were adjusted for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, and admission source. c Additional covariates included in the model: patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient. d Additional covariates included in the model: site e OR=odds ratio. Results from ordinal logistic regression modeling. f Additional covariates included in the model: patient s race (black vs. non-black) g OR=odds ratio. Results from logistic regression modeling. h Additional covariates included in the model: surrogate s age and gender <
22 Table S6. Effect of PARTNER Intervention on surrogates psychological distress stratified by whether the patient survived the index hospitalization Patient survived hospitalization PARTNER Intervention Adjusted effect (95% CI) p-value a Patient died in-hospital PARTNER Intervention effect (95% CI) Adjusted p-value a Surrogates Psychological Outcomes (n=568) (n=241) HADS (range 0-42) b β (-1.71 to 1.47) c 0.88 β (-3.94 to 1.26) c 0.31 IES (range 0-88) β 0.65 (-2.31 to 3.61) c 0.67 β 0.37 (-4.90 to 5.64) c 0.89 a Adjusted for patient s age, modified SAPS III, Elixhauser index, mechanical ventilation usage, admission source, patient s vital status up to 6-month post-discharge, surrogate s gender and relationship to the patient. b Additional covariates included in the model: site c β=linear regression coefficient. Results from adjusted linear regression model. 20
23 Trial Registration and Designation as Quality Improvement Project The University of Pittsburgh Institutional Review Board, the UPMC Quality Improvement Committee, and the leadership of participating ICUs approved the project. The deployment of the intervention was judged to be a quality improvement project because its primary purpose was to increase the implementation of behaviors recommended in professional society practice statements (e.g., provision of emotional support and timely conduct of interdisciplinary family meetings). All surrogates of eligible patients were informed of the quality improvement project by clinical staff. The long-term follow up of surrogates was judged to be research; therefore, surrogates provided informed consent for participation. Due to an administrative error by the research team regarding whether quality improvement projects could be registered on clinicaltrials.gov, trial registration was finalized after subject enrollment commenced. The timeline was as follows: 1. UPMC approved the study protocol on June 18, 2012 (one month before the trial was started). This institutional review concluded that the project was a quality improvement project and therefore would not be issued an IRB approval number. 2. Before the first patient was enrolled the study coordinator attempted to register the trial on the clinical trials registration site (clinicaltrials.gov). However, when she encountered the portion of the registration process that requests the IRB approval number, she interpreted the instructions on the website to mean that she could not formally submit the application without an IRB approval and therefore did not finalize the registration. 3. Due to a miscommunication, the study PI believed that the outcome was that the research coordinator had indeed certified the registration and only needed to go back to update the site once we secured an IRB approval number. 4. Because the project was deemed QI by the institution and was approved to begin, subject enrollment proceeded. 5. In order to be able to add an IRB number to the trial registration site, we requested that the IRB review the project as human subjects research. We were eventually permitted to submit an IRB application which, after several iterations, was approved on 2/26/2013. Only the long-term follow up of surrogates was judged to be research requiring consent. 6. On April 19, 2013, the research coordinator entered the IRB approval number and finalized the submission on the clinical trials registration website. 21
24 Schedule of PARTNER Program 12-Hour Communication Skills Training DAY 1 8:15--8:30 a.m. Registration and Breakfast 8:30--9:00 a.m. PARTNER Overview 9:00--9:30 a.m. Overview of Core Communication Skills 9:30--10:00 a.m. First Meeting with Family (Didactic/modeling) 10:00 10:45 a.m. Skills Practice I: First Meeting with Family 10:45--11:00 a.m. BREAK 11:00 11:45 a.m. Skills Practice ll: First Meeting with Family 11:45 am--12:15 p.m. LUNCH 12:15--12:30 p.m. Making Family Meetings Happen 12:30--1:00 p.m. Pre-Family Meeting (Didactic/modeling) 1:00--2:00 p.m. Skills Practice lll: Pre-Family Meeting 2:00--2:15 p.m. BREAK 2:15--2:30 p.m. Daily Check-in (Didactic/modeling) 2:30--3:00 p.m. Skills Practice lv: Daily Check-in 3:00--3:15 p.m. Taking the Skills Home 3:15--3:30 p.m. Next steps and Program Evaluation 22
25 DAY 2 8:00--8:15 a.m. Registration and Breakfast 8:15--8:30 a.m. Overview of Today - Intervention Training Day 2 --Pre Meeting with Doctors --Family Meetings --Post-Family Meeting 8:30--8:45 a.m. Review and Model Key Activities of PARTNER Program (Intervention Training Day 1) -- First Meeting with Family --Pre-Family Meeting --Daily Check-in --Making Family Meetings Happen 8:45--9:00 a.m. 9:00 9:30 a.m. Pre Meeting with Doctors -- Didactic Talk -- Role Model Skills Pre Meeting with Doctors --Skills Practice 9:30--9:45 a.m. Gently Intervening in Family Meetings -- Didactic Talk -- Role Model Skills 9:45--10:45 a.m. 10:45 a.m.--11:15 a.m. 11: :45 a.m. 11:45 12:15 p.m. 12:15 12:30 p.m. 12:30 12:45 p.m. Gently Intervening: Skills Practice --Practice Activities/Skills --Gently Intervening Skills Practice LUNCH Review and Model Skills for Post-Family Meeting --Skills Practice Documentation Q & A Program Evaluation 23
26 PARTNER Question Prompt List Questions About My Loved One It s normal for families to have questions about what is happening with their loved one s illness and treatment. Please check the questions that you would like the doctor or ICU team to answer. Disease Information What is wrong with my loved one? What treatments is my loved one receiving? Prognosis What happens to most people with the kind of illness my loved one has? My Loved One s Values How can I make sure the doctors know about my loved one s values and treatment preferences? What should my role be in making treatment decisions? Options What are the different treatment options that we should be thinking about? Milestones How can we tell if my loved one is getting better or worse? Social How do people cope with having a loved one in the ICU? How do most people discuss the stress of having someone in the ICU with their family and friends? Who can provide information about insurance and financial issues? Is there a chaplain or other spiritual support available in the hospital? What should I do if I get conflicting information from the different doctors? Please write any other questions you have for the care team: Questions the Doctor May Ask You: Have you ever made decisions for a loved one who was too sick to make decisions? What was your loved one like before this hospitalization. What does he or she do/enjoy? Has your loved one ever talked about treatment preferences and values if he or she were very sick? What role would you like to play in major medical decisions for your loved one? 24
27 Comparison of PARTNER intervention and SUPPORT intervention The SUPPORT and PARTNER interventions are conceptually and practically very different. The SUPPORT intervention was grounded in traditional decision theory (i.e., utility theory) and focused on providing clinicians accurate information about patients prognosis and preferences. 1 In contrast, the PARTNER intervention was grounded in Kahneman and Tversky s prospect theory 2, and was designed to support surrogates through the emotional and psychological complexity of making decisions for others. Second, we used methods of implementation science to intervene on ICUs culture and practices related to family support. Third, the PARTNER intervention was delivered by the interprofessional ICU team rather than by external interventionists, which may have led to more integrated and effective support of surrogates. 1. Lynn J, Arkes HR, Stevens M, et al. Rethinking fundamental assumptions: SUPPORT's implications for future reform. Study to Understand Prognoses and Preferences and Risks of Treatment. J Am Geriatr Soc 2000;48:S Kahneman, Daniel. A Perspective on Judgment and Choice: Mapping Bounded Rationality. American Pyschologist. 2003; 58:
The Influence of Race and Ethnicity on End-of-Life Care in the Intensive Care Unit
The Influence of Race and Ethnicity on End-of-Life Care in the Intensive Care Unit Sarah Muni, MD Department of Medicine Chair s Rounds November 10, 2009 Health Disparities Research Clinical appropriateness
More informationnicheprogram.org 2015 Annual NICHE Conference Innovation Through Leadership Background
Wii Can Too! Using Gaming Technology with Hospital Elder Life Program Patients Megan Wheeler, MSN, RN, ACNS-BC Janice F. Moore, PhD, CFLE Background Grant Proposal Hospital Elder Life Program (HELP) proven
More informationIdentify essential primary palliative care (PPC) communication skills that every provider needs AND clinical triggers for PPC conversations
Identify essential primary palliative care (PPC) communication skills that every provider needs AND clinical triggers for PPC conversations Esmé Finlay, MD Division of Palliative Medicine University of
More informationSupplementary Online Content
Supplementary Online Content Rollman BL, Herbeck Belnap B, Abebe KZ, et al. Effectiveness of online collaborative care for treating mood and anxiety disorders in primary care: a randomized clinical trial.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationAchieving earlier entry to hospice care: Issues and strategies. Sonia Lee, APN, GCNS-BC
Achieving earlier entry to hospice care: Issues and strategies Sonia Lee, APN, GCNS-BC Objectives The learner will: Describe the benefits of hospice List at least barriers to early hospice care List at
More informationSupplementary Online Content
Supplementary Online Content Gershengorn HB, Scales DC, Kramer A, Wunsch H. Association between overnight extubations and outcomes in the intensive care unit. JAMA Intern Med. Published online September
More informationSupplementary Online Content
Supplementary Online Content Lee JS, Nsa W, Hausmann LRM, et al. Quality of care for elderly patients hospitalized for pneumonia in the United States, 2006 to 2010. JAMA Intern Med. Published online September
More informationApproved Care Model for Project 3gi: Integration of Palliative Care into the PCMH Model
1 Approved Care Model for Project 3gi: Integration of Palliative Care into the PCMH Model OneCity Health Webinar January 13, 2016 Overview of presentation 2 Approach to care model development Project overview
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and
More informationDr Sylvie Lambert, RN, PhD
Is it the most frequent unmet supportive care needs that predict caregivers anxiety and depression? Results from Australia s Partners and Caregivers Longitudinal Well-being Study Dr Sylvie Lambert, RN,
More informationChapter 6. Hospice: A Team Approach to Care
Chapter 6 Hospice: A Team Approach to Care Chapter 6: Hospice: A Team Approach to Care Comfort, Respect and Dignity in Dying Hospice care provides patients and family members with hope, comfort, respect,
More informationGeriatric Emergency Management PLUS Program Costing Analysis at the Ottawa Hospital
Geriatric Emergency Management PLUS Program Costing Analysis at the Ottawa Hospital Regional Geriatric Program of Eastern Ontario March 2015 Geriatric Emergency Management PLUS Program - Costing Analysis
More information12/6/2016. Objective PALLIATIVE CARE IN THE NURSING HOME. Medical Care in the US. Palliative Care
Objective PALLIATIVE CARE IN THE NURSING HOME Deborah Morris, M.D., M.H.S. Assistant Professor of Medicine The Glennan Center for Geriatrics and Gerontology Eastern Virginia Medical School Describe program
More informationNational Landscape of Hospital-Based Palliative Care: Findings from the National Palliative Care Registry
National Landscape of Hospital-Based Palliative Care: Findings from the National Palliative Care Registry Maggie Rogers, MPH Senior Research Associate, CAPC Tamara Dumanovsky, PhD VP Research & Analytics,
More informationUpdate on the Cambia Palliative Care Center of Excellence at UW
Update on the Cambia Palliative Care Center of Excellence at UW J. Randall Curtis, MD, MPH Director, Cambia Palliative Care Center of Excellence Harborview Medical Center, University of Washington www.uwpalliativecarecenter.com
More informationQuality of Life after. A Critical Illness: A review of the literature
1 Quality of Life after A Critical Illness: A review of the literature 1998 2003 by Harriet Adamson BN MAdEd A Thesis submitted in fulfillment of the requirements for the degree Master of Nursing (Honours)
More informationPatient and Family Agreement on Opioids
Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from
More informationCambia Palliative Care Metrics: Where are we and where are we going?
Cambia Palliative Care Metrics: Where are we and where are we going? J. Randall Curtis, MD, MPH Director, Cambia Palliative Care Center of Excellence www.uwpalliativecarecenter.com Overview of System-Wide
More informationPalliative Care for Older Adults in the United States
Palliative Care for Older Adults in the United States Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Icahn School
More informationUPMC Critical Care
UPMC Critical Care www.ccm.upmc.edu CRISMA Critical Care Medicine the University of Pittsburgh Optimal use of ICU resources Derek C. Angus, MD, MPH, FRCP The CRISMA Laboratory Critical Care Medicine School
More informationHospice and Palliative Care: Value-Based Care Near the End of Life
Hospice and Palliative Care: Value-Based Care Near the End of Life Mary Dittrich, MD, FASN Senior Medical Director, Remedy Partners Joseph W. Shega, MD National Medical Director, VITAS Healthcare 2017
More informationPubH 7405: REGRESSION ANALYSIS. Propensity Score
PubH 7405: REGRESSION ANALYSIS Propensity Score INTRODUCTION: There is a growing interest in using observational (or nonrandomized) studies to estimate the effects of treatments on outcomes. In observational
More informationHospice and Palliative Care: Value-Based Care Near the End of Life
Hospice and Palliative Care: Value-Based Care Near the End of Life Mary Dittrich, MD, FASN Senior Medical Director, Remedy Partners Joseph W. Shega, MD National Medical Director, VITAS Healthcare 2017
More informationA Very Early Rehabilitation Trial (AVERT): What we know, what we think and what s to come
A Very Early Rehabilitation Trial (AVERT): What we know, what we think and what s to come The AVERT Trial Collaboration group Joshua Kwant, Blinded Assessor 17 th May 2016 NIMAST Nothing to disclose Disclosure
More informationAPPENDIX: Supplementary Materials for Advance Directives And Nursing. Home Stays Associated With Less Aggressive End-Of-Life Care For
Nicholas LH, Bynum JPW, Iwashnya TJ, Weir DR, Langa KM. Advance directives and nursing home stays associated with less aggressive end-of-life care for patients with severe dementia. Health Aff (MIllwood).
More informationThere For You. Your Compassionate Guide. World-Class Hospice Care Since 1979
There For You Your Compassionate Guide World-Class Hospice Care Since 1979 What Is Hospice? Hospice is a type of care designed to provide support during an advanced illness. Hospice care focuses on comfort
More informationPain Rehabilitation Executive Program
Pain Rehabilitation Executive Program The Mayo Clinic Pain Rehabilitation Executive Program (PREP) is an intensive 2-day rehabilitation program for patients with chronic pain. The PREP provides an overview
More informationA snapshot of inpatient oncology rehabilitation: Patient profiles and rehab outcomes Rehabilitation Rounds, University of Toronto April 5, 2012
A snapshot of inpatient oncology rehabilitation: Patient profiles and rehab outcomes Rehabilitation Rounds, University of Toronto April 5, 2012 Sara McEwen, PT, PhD Research Scientist, St. John s Rehab
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Chan PS, Nallamothu BK, Krumholz HM, et al. Long-term outcomes
More informationImpact of Florida s Medicaid Reform on Recipients of Mental Health Services
Impact of Florida s Medicaid Reform on Recipients of Mental Health Services Jeffrey Harman, PhD John Robst, PhD Lilliana Bell, MHA The Quality of Behavioral Healthcare : A Drive for Change Through Research
More informationLearning Goals: REMAP: Discussing Goals of Care. Reframe. 2. Expect emotion: respond empathically. 2. Expect emotion: respond empathically
Practicing patient centered medicine in the 4th quarter Bob Arnold MD 2016 Learning Goals: To define the difference between goals and strategy To describe a goal focused method of talking with patients
More informationPalliative Care Quality Improvement Program (QIP) Measurement Specifications
Palliative Care Quality Improvement Program (QIP) 2017-18 Measurement Specifications Developed by: QIP Team Contact: palliativeqip@partnershiphp.org Published on: October 6, 2017 Table of Contents Program
More informationPalliative Care: A Business Analysis of the Pros and Cons of Establishing a Palliative Care Program
1 Palliative Care: A Business Analysis of the Pros and Cons of Establishing a Palliative Care Program Daniel Maison, MD Larry Oberst, CPA Spectrum Health 2 Faculty Information Daniel Maison, MD FAAHPM
More informationCARE 4 Us: Promoting Improvements in Palliative Care in SE PA
Compassion * Advocacy * Respect * Empowerment Building foundations for strong palliative care programs CARE 4 Us: Promoting Improvements in Palliative Care in SE PA Susan Choi, PhD, CPHQ March 19, 2014
More informationClinical Trial of a Supportive Care Team for Patients With Advanced Cancer
Vol. 46 No. 6 December 2013 Journal of Pain and Symptom Management 775 Original Article Clinical Trial of a Supportive Care Team for Patients With Advanced Cancer Barbara J. Daly, PhD, RN, FAAN, Sara L.
More informationSupplementary Online Content
Supplementary Online Content Callaghan B, McCammon R, Kerber K, Xu X, Langa KM, Feldman E. Tests and expenditures in the initial evaluation of peripheral neuropathy. Arch Intern Med. 2012;172(2):127-132.
More informationAntidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors
Antidepressant Use in ICU Survivors 1 Antidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors Sophia Wang, MD, Chris Mosher, MD, Sujuan Gao, PhD, Kayla Kirk, MA, Sue Lasiter, PhD, RN,
More informationA Decade of Data: Findings and Insights from the National Palliative Care Registry
A Decade of Data: Findings and Insights from the National Palliative Care Registry Maggie Rogers, MPH Senior Research Manager, CAPC Rachael Heitner, MA, CHPCA Research Associate, CAPC July 19, 2018 at
More informationIntegrated Care for Depression, Anxiety and PTSD. Introduction: Overview of Clinical Roles and Ideas
Integrated Care for Depression, Anxiety and PTSD University of Washington An Evidence-based d Approach for Behavioral Health Professionals (LCSWs, MFTs, and RNs) Alameda Health Consortium November 15-16,
More informationArts Administrators and Healthcare Providers
Arts Administrators and Healthcare Providers Table of Contents Part One: Creating Music and Programs 2 Preparing to Start a Program 2 Finding Funding 2 Selecting Partner Arts Organizations or Healthcare
More informationCancer and Advance Care Planning You ve been diagnosed with cancer. Now what?
Cancer and Advance Care Planning You ve been diagnosed with cancer. Now what? ACP Cancer Booklet-- Patient_FINAL.indd 1 You have a lot to think about and it can be difficult to know where to start. One
More informationQuality and Fiscal Metrics: What Proves Success?
Quality and Fiscal Metrics: What Proves Success? 1 Quality and Fiscal Metrics: What Proves Success? Kathleen Kerr Kerr Healthcare Analytics Creating the Future of Palliative Care NHPCO Virtual Event February
More informationIntegration of Palliative Care into Standard Oncology Care. Esther J. Luo MD Silicon Valley ONS June 2, 2018
Integration of Palliative Care into Standard Oncology Care Esther J. Luo MD Silicon Valley ONS June 2, 2018 Objectives Become familiar with the literature illustrating the benefits of palliative care in
More informationEssential Skills for Evidence-based Practice: Statistics for Therapy Questions
Essential Skills for Evidence-based Practice: Statistics for Therapy Questions Jeanne Grace Corresponding author: J. Grace E-mail: Jeanne_Grace@urmc.rochester.edu Jeanne Grace RN PhD Emeritus Clinical
More informationNational Stroke Association s Guide to Choosing Stroke. Rehabilitation Services
National Stroke Association s Guide to Choosing Stroke Rehabilitation Services Rehabilitation, often referred to as rehab, is an important part of stroke recovery. Through rehab, you: Re-learn basic skills
More informationBRIGHAM AND WOMEN S FAULKNER HOSPITAL ADULT INPATIENT PSYCHIATRY ADVANCED PRACTICUM TRAINING PROGRAM
BRIGHAM AND WOMEN S FAULKNER HOSPITAL ADULT INPATIENT PSYCHIATRY ADVANCED PRACTICUM TRAINING PROGRAM 2019-2020 Christopher AhnAllen, Ph.D. Director of Inpatient Psychology and Psychology Education 1153
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationNational Palliative Care Registry : Hospital Palliative Care Preview
National Palliative Care Registry : Hospital Palliative Care Preview Maggie Rogers, MPH Senior Research Associate, CAPC Tamara Dumanovsky, PhD VP Research & Analytics, CAPC September 15, 2016 The National
More informationClinical Epidemiology for the uninitiated
Clinical epidemiologist have one foot in clinical care and the other in clinical practice research. As clinical epidemiologists we apply a wide array of scientific principles, strategies and tactics to
More informationSocial Participation Among Veterans With SCI/D: The Impact of Post Traumatic Stress Disorder
Social Participation Among Veterans With SCI/D: The Impact of Post Traumatic Stress Disorder Bella Etingen, PhD 1 ;Sara M. Locatelli, PhD 1 ;Scott Miskevics, BS 1 ; Sherri L. LaVela, PhD, MPH, MBA 1,2
More informationWe need to talk about Palliative Care COSLA
Introduction We need to talk about Palliative Care COSLA 1. Local government recognises the importance of high quality palliative and end of life care if we are to give people greater control over how
More informationOptimizing Communication of Emergency Response Adaptive Randomization Clinical Trials to Potential Participants
1. Background The use of response adaptive randomization (RAR) is becoming more common in clinical trials (Journal of Clinical Oncology. 2011;29(6):606-609). Such designs will change the randomization
More informationPatient Outcomes in Palliative Care for South Australia
Patient Outcomes in Palliative Care for South Australia July to December 215 PCOC is a national palliative care project funded by the Australian Government Department of Health The Palliative Care Outcomes
More informationUniversal Screening for Palliative Needs
P A L L I A T I V E C A R E NO PATIENT LEFT BEHIND Universal Screening for Palliative Needs BY MARY HICKS, RN, MSN, APRN AND ELIZABETH DISTEFANO, RN, BSN How can health care providers be confident their
More informationNighttime ICU Physician Staffing
Nighttime ICU Physician Staffing Scott D. Halpern, M.D., Ph.D. Assistant Professor of Medicine, Epidemiology, and Medical Ethics & Health Policy Director, Fostering Improvement in End-of-Life Decision
More informationApproaching Patients and Family Members Who Hope for a Miracle. Eric Widera, M.D. Division of Geriatrics, UCSF Blog: geripal.org
Approaching Patients and Family Members Who Hope for a Miracle Eric Widera, M.D. Division of Geriatrics, UCSF Blog: geripal.org Twitter: @ewidera The lens of the provider The lens of the family The Case
More informationPerformance of PROMIS and Legacy Measures Among Advanced Breast Cancer Patients and Their Caregivers
Performance of PROMIS and Legacy Measures Among Advanced Breast Cancer Patients and Their Caregivers Alla Sikorskii, PhD Department of Psychiatry Department of Statistics and Probability Michigan State
More informationHospice and Palliative Care An Essential Component of the Aging Services Network
Hospice and Palliative Care An Essential Component of the Aging Services Network Howard Tuch, MD, MS American Academy of Hospice and Palliative Medicine Physician Advocate, American Academy of Hospice
More informationAdverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease
Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease J. Sukanya 05.Jul.2012 Outline Background Methods Results Discussion Appraisal Background Common outcomes in hospitalized
More informationCounseling & Support. Elder Medical Care. Hospice Care
Counseling & Support Elder Medical Care Hospice Care Mission To provide counseling, support and care to anyone with a serious illness, so they may live life to the fullest. Vision We are deeply committed
More informationPregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system
Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system The Harvard community has made this article openly available. Please share how this
More informationFINANCES OF PALLIATIVE CARE
FINANCES OF PALLIATIVE CARE Andrew Molosky, MBA Vice President of Operations Seasons Hospice & Palliative Care Learning Objectives: Distinguish and identify the unique needs of one's organization as it
More informationBiostatistics Primer
BIOSTATISTICS FOR CLINICIANS Biostatistics Primer What a Clinician Ought to Know: Subgroup Analyses Helen Barraclough, MSc,* and Ramaswamy Govindan, MD Abstract: Large randomized phase III prospective
More informationThe New Center for Palliative Care at the Ithaca College Gerontology Institute
The New Center for Palliative Care at the Ithaca College Gerontology Institute Barbara Ganzel, Ph.D., LMSW, Gerontology Institute Director Elizabeth Bergman, Ph.D., Associate Professor Center for Palliative
More informationAt the. End of Life. difficult conversations about. organ donation
At the End of Life difficult conversations about organ donation Hope is the power of being cheerful in circumstances we know to be desperate. Hope is an attachment to something I believe that I do not
More informationWHAT FACTORS INFLUENCE AN ANALYSIS OF HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011
WHAT FACTORS INFLUENCE HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AN ANALYSIS OF AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011 WHAT IS AGGRESSIVE EOL CARE? Use of ineffective medical
More informationPalliative Care: Mission and Strategic Imperative. Sarah E. Hetue Hill, PhD Ascension Healthcare
Palliative Care: Mission and Strategic Imperative Sarah E. Hetue Hill, PhD Ascension Healthcare Ascension Palliative Care Definition Palliative Care is person-centered, holistic care delivered by an interdisciplinary
More informationPsychological outcomes of cri2cal illness for pa2ents and family members. Erin K. Kross, MD Summer Lung Day June 18, 2010
Psychological outcomes of cri2cal illness for pa2ents and family members Erin K. Kross, MD Summer Lung Day June 18, 2010 Outline Overview of psychological outcomes for pa2ents and family members ager cri2cal
More informationNorthwestern University. Consent Form and HIPAA Authorization for Research
Northwestern University Consent Form and HIPAA Authorization for Research PROTOCOL TITLE: Yoga Versus Resistance Training in Parkinson s Disease: A Randomized, Controlled Pilot Study of Feasibility & Efficacy
More informationLUNG CANCER CLINICAL TRIALS
UNDERSTANDING SERIES LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT THE BASICS ABOUT CLINICAL TRIALS WITH MORE INFORMATION YOU CAN MAKE BETTER CHOICES. The decision
More informationVirtual & Onsite Patient-Developed Mental Health Groups
Virtual & Onsite Patient-Developed Mental Health Groups Magda Czegledi MD Sue Miller ICD.D Mental Wellness Recovery 1 Presenter Disclosure Presenter: Magda Czegledi Relationships that may introduce potential
More informationThere Is Something More We Can Do: An Introduction to Hospice and Palliative Care
There Is Something More We Can Do: An Introduction to Hospice and Palliative Care presented to the Washington Patient Safety Coalition July 28, 2010 Hope Wechkin, MD Medical Director Evergreen Hospice
More informationSurvey of Smoking, Drinking and Drug Use (SDD) among young people in England, Andrew Bryant
Survey of Smoking, Drinking and Drug Use (SDD) among young people in England, 2010 Andrew Bryant Newcastle University Institute of Health and Society Background Background Young people s drinking behaviour
More informationNATIONAL REHABILITATION HOSPITAL (NRH) THE SPINAL CORD SYSTEM OF CARE (SCSC) PROGRAMME INPATIENT SCOPE OF SERVICE
NATIONAL REHABILITATION HOSPITAL (NRH) THE SPINAL CORD SYSTEM OF CARE (SCSC) PROGRAMME INPATIENT SCOPE OF SERVICE NATIONAL REHABILITATION HOSPITAL SCOPE OF SERVICE FOR THE SPINAL CORD SYSTEM OF CARE PROGRAMME
More informationFacilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)
Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Data Analysis Plan: Apneic Oxygenation vs. No Apneic Oxygenation Background Critically ill patients
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
A Contemporary, Population-Based Analysis of the Incidence, Cost, Outcomes, and Preoperative Risk Prediction of Postoperative Delirium Following Major Urologic Cancer Surgeries The Harvard community has
More informationABCDEF Bundle Breakout
ABCDEF Bundle Breakout Andrew Masica, MD, MSCI VP, Chief Clinical Effectiveness Officer Baylor Scott & White Health andrew.masica@bswhealth.org Disclosures/Funding Support Grant R18-HS021459 from the Agency
More informationTHE ROLE OF PALLIATIVE CARE IN TREATMENT OF PATIENTS WITH CHRONIC, INFECTIOUS DISEASE
THE ROLE OF PALLIATIVE CARE IN TREATMENT OF PATIENTS WITH CHRONIC, INFECTIOUS DISEASE JESSICA MCFARLIN MD ASSISTANT PROFESSOR OF NEUROLOGY DIVISION CHIEF, PALLIATIVE AND SUPPORTIVE CARE I HAVE NO COI OR
More informationClinical Practice Guidelines for Quality Palliative Care, 4 th edition
Welcome Clinical Practice Guidelines for Quality Palliative Care, 4 th edition Webinar December 17, 2:00 4:30 PM ET Webinar Host: www.nationalcoalitionhpc.org Moderator: Amy Melnick, MPA Executive Director
More informationBrenda Schmitthenner, MPA
Brenda Schmitthenner, MPA 1 San Diego s ADRC implemented Care Transitions Intervention (CTI) in August 2010 Evidence based Coleman Model to coach, not do, using Four Pillars Establish and maintain a PHR
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationPosttraumatic Stress Disorder and Suicidal Behavior: Current Understanding and Future Directions
Posttraumatic Stress Disorder and Suicidal Behavior: Current Understanding and Future Directions Jaimie L. Gradus, DSc, MPH Epidemiologist, National Center for PTSD, VA Boston Healthcare System Associate
More informationOccupational therapy after stroke
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Occupational therapy after stroke This guide explains how occupational therapy can help your recovery and rehabilitation after a stroke.
More informationHome Health Value-Based Purchasing (HHVBP)
Home Health Value-Based Purchasing (HHVBP) Improving Performance with Pain: OASIS and HHCAHPS Measures June 1, 2017 Prepared for CMS by the HHVBP Technical Assistance, contract number HHSM-500-2014-0033I.
More informationThe Perspectives Program
The Perspectives Program A new psychosocial treatment research program for verbal individuals, ages 16-40, with Autism Spectrum Disorders Supported by: National Institute of Mental Health, Autism Speaks
More informationIn this monthly feature, NewsLine
In this monthly feature, NewsLine shines the light on a hospice organization which has expanded services or has partnered with other community organizations to reach patients earlier in the illness trajectory
More informationPalliative Care in the Continuum of Oncologic Management
Palliative Care in the Continuum of Oncologic Management PC in the Routine Continuum of Cancer Care Michael W. Rabow, MD Director, Symptom Management Service Helen Diller Family Comprehensive Cancer Center
More informationThe National Palliative Care Registry and Impact on the Field of Palliative Care
The National Palliative Care Registry and Impact on the Field of Palliative Care Diane E. Meier Director, Center to Advance Palliative Care (CAPC) diane.meier@mssm.edu registry.capc.org April 25, 2018
More informationOccupational therapy after stroke
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Occupational therapy after stroke This guide explains how occupational therapy can help your recovery and rehabilitation after a stroke.
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationA Policy Relevant US Trauma Care System Pragmatic Trial for PTSD & Comorbidity (UH2 MH )
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD & Comorbidity (UH2 MH106338-01) Douglas Zatzick, MD Professor, Department of Psychiatry and Behavioral Sciences Harborview Level I Trauma
More informationStatistical Analysis Plan
The BALANCED Anaesthesia Study A prospective, randomised clinical trial of two levels of anaesthetic depth on patient outcome after major surgery Protocol Amendment Date: November 2012 Statistical Analysis
More informationPALLIATIVE CARE IN NEW YORK STATE
Collaborative for Palliative Care In collaboration with its partners End of Life Choices New York Finger Lakes Geriatric Education Center at the University of Rochester COLLABORATIVE FOR PALLIATIVE CARE
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDIOXIN SYMPOSIUM MEETING PLANNING
DIOXIN SYMPOSIUM MEETING PLANNING History & General Information A listing of future and past Dioxin Symposia can be found on the Symposium page. The International Dioxin Symposium has been held annually
More informationThe Future of Healthcare is Now. AMSUS November 2018 Steven L. Lieberman, MD, MBA, FACHE Interim Executive in Charge, Veterans Health Administration
VA The Future of Healthcare is Now AMSUS November 2018 Steven L. Lieberman, MD, MBA, FACHE Interim Executive in Charge, Veterans Health Administration WHO ARE WE? 4 Statutory Missions: Health Care, Education
More informationCancer Committee Report to the Community
2014 Cancer Committee Report to the Community 2014 CANCER COMMITTEE MEMBERS Martha Hosford, MD Chairperson & Medical Oncology Jamil Khatri, MD Cancer Conference Coordinator Elizabeth Lowe, MD Breast Program
More informationMulti-institutional Evaluation of Adherence to Comprehensive Postoperative Venous Thromboembolism Chemoprophylaxis
Multi-institutional Evaluation of Adherence to Comprehensive Postoperative Venous Thromboembolism Chemoprophylaxis D. Brock Hewitt MD MPH, Eddie Blay Jr MD, Lindsey J Kreutzer MPH, Thomas E Kmiecik PhD,
More informationPediatric Palliative Care and Having Difficult Conversations
Pediatric Palliative Care and Having Difficult Conversations UCSF Pediatric Neurology and Palliative Care Audrey Foster-Barber, MD, PhD Pediatric Hospital Medicine Boot Camp 6/14 Palliative Care A philosophy
More information